[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534127":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":19,"responsibleParty":39,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":22,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Universidad Europea de Madrid","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"ICU Patients",null,"Patients admitted to the Intensive Care Unit (ICU) at HLA Moncloa Hospital",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Samuel G González, Doctor","CONTACT","34692619904","samuelgonlop@gmail.com",{"name":14,"role":15,"phone":10,"phoneExt":10,"email":17},[20],{"facility":21,"status":22,"city":23,"state":10,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Hospital Universitario HLA Moncloa","RECRUITING","Madrid","28035","Spain","ES",{"type":28,"coordinates":29},"Point",[30,31],-3.70256,40.4165,{"lat":31,"lon":30},[34,36],{"name":35,"role":15,"phone":16,"phoneExt":10,"email":17},"Gonzalez S González S, Doctor",{"name":37,"role":38,"phone":10,"phoneExt":10,"email":10},"Samuel G Gonzalez S, Doctor","PRINCIPAL_INVESTIGATOR",{"type":38,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Samuel Gonzalez Lopez","Principal Investigator","100534127","continuous-subcutaneous-glucose-monitoring-in-critical-patients-100534127",false,"NCT06234787","Continuous Subcutaneous Glucose Monitoring in Critical Patients","Continuous Subcutaneous Glucose Monitoring: A Descriptive Study of Its Use in Critical Patients","Inclusion Criteria:\n\n* The study will be conducted in patients admitted to the ICU of HLA Moncloa Hospital over four years. Patients admitted to the ICU, undergoing insulin treatment, and having a CGM sensor.\n* Patients who sign the voluntary consent to participate in the study (Annex 2). If the participant is not in full physical or intellectual capacity to provide their signature on the informed consent, the responsible investigator will request such consent from their direct family member or the person legally designated to make decisions on their behalf regarding health matters. This measure is taken to ensure that the participant\\'s rights are respected, and the integrity of the consent process is maintained, even in situations where their decision-making capacity may be compromised.\n\nExclusion Criteria:\n\n* Patients from whom information on CGM cannot be obtained for technical reasons.","ALL","18 Years",{"count":52,"type":53},245,"ESTIMATED","OBSERVATIONAL","This is a single-center, observational, descriptive, longitudinal, and prospective study This study aims to determine the cumulative incidence during admission and the incidence rate of potential hypoglycemic events (defined as subcutaneous glucose \\\u003C80 mg\u002FdL detected by CGM) in patients admitted to the Intensive Care Unit (ICU) of HLA Moncloa Hospital over four years of follow-up. The study also aims to document the occurrences of hypoglycemic events, describe the characteristics of patients receiving CGM sensors, and outline the actions taken as a result of detecting potential hypoglycemic events",[57,58,59,60,61],"Hyperglycemia","Hypoglycemia","Diabetes","Critical Care","Critically Ill Patients",[63,64,65,66],"continuous subcutaneous glucose monitoring","critical care","intensive care","hypoglycemia","2024-02-01",{"date":69,"type":70},"2024-02-05","ACTUAL",{"date":72,"type":70},"2023-11-30",{"date":74,"type":53},"2027-12-01",{"name":5,"class":6},1]